文献速递脑血管病

依达拉奉右莰醇对比依达拉奉治疗急性缺血性卒中:III期随机双盲对照试验

Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
PubMed 文献 · Stroke · 2021-02-16

结果显示依达拉奉右莰醇组改良Rankin量表评分≤1的比例显著更高(67.18% vs 58.97%),尤其在女性患者中获益更明显。

要点

  • 依达拉奉右莰醇组90天良好功能结局比例显著高于依达拉奉组。
  • 女性患者从依达拉奉右莰醇治疗中获益大于男性患者。
  • 两药均在卒中发病48小时内开始给药,疗程14天。

核心结论

  • 急性缺血性卒中发病48小时内给予依达拉奉右莰醇,90天良好功能结局优于依达拉奉,女性患者获益更明显。

主要发现

  • 依达拉奉右莰醇组90天改良Rankin量表评分≤1的比例为67.18%,依达拉奉组为58.97%,比值比1.42(95%CI 1.12-1.81),P=0.004。
  • 预设亚组分析显示女性患者比值比2.26(95%CI 1.49-3.43),男性患者比值比1.14(95%CI 0.85-1.52)。

关键数值与推荐

  • 纳入标准:诊断为急性缺血性卒中,年龄35至80岁,美国国立卫生研究院卒中量表评分4至24分,发病48小时内。
  • 主要终点:随机化后90天改良Rankin量表评分≤1的患者比例。
  • 治疗方案:14天输注依达拉奉右莰醇或依达拉奉注射液。

临床怎么用

  • 对于符合入选标准的急性缺血性卒中患者,可考虑在发病48小时内使用依达拉奉右莰醇以改善90天功能结局。
  • 女性急性缺血性卒中患者可能从依达拉奉右莰醇治疗中获益更显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). METHODS: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. RESULTS: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12-1.81]; P=0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49-3.43 versus 1.14, 0.85-1.52). CONCLUSIONS: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02430350.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Xu J, Wang A, Meng X, et al. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. 2021. PMID: 33588596. doi:10.1161/STROKEAHA.120.031197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。